In a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.

MSKCC’s Dr. Alexander Drilon highlights other known alterations that are being targeted or being used as biomarkers in non–small-cell lung cancer.

Dr. Hossein Borghaei discusses results of the Checkmate 227 trial and its impact on treatment decision-making in NSCLC.

Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.

Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.

USPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.

Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.

In this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.

Joshua Brody discusses ECHELON-1 and its subanalyses, the results of which are anticipated to change the management of Hodgkin lymphoma.

Medical oncologist Ryan J. Sullivan shared some interesting melanoma-related presentations from the  2018 ASCO Annual Meeting.

MSKCC’s Dr. Nancy Kemeny discusses the impact of a company's decision to halt manufacture of a pump used to treat liver mets from colon and rectal cancers.

In this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS’s role in developing an ASCO/NCCN guideline for their management.

During AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.

In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic.

Drs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.

Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.

Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.

In this interview we discuss preliminary results of the COMPASS trial, which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.

In this interview, we discuss the results of the phase III MURANO trial, which tested the combination of venetoclax with rituximab in relapsed/refractory CLL.

In this interview, we discuss a mathematical model that was created to predict patient response to immunotherapy for cancer treatment.

In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.

In this interview we discuss the goals of therapy in multiple myeloma, treatment combinations and transplantation, and how markers such as minimal residual disease are used.

In this interview, we discuss the biology and the therapeutic strategies for primary mediastinal B-cell lymphoma.

In this interview ahead of the ASH Annual Meeting we discuss the current management of Philadelphia chromosome–positive acute lymphoblastic leukemia and the role of stem cell transplantation.

In this interview, we discuss an assay that can detect disease recurrence in colorectal cancer patients.

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

In this interview we discuss a recent study that linked periodontal disease with an increased cancer risk, specifically melanoma and cancers of the lung, breast, esophagus, and gallbladder.

In this interview we discuss the ASCO provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer.

In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.